Tuesday 10 November 2015
Activist Investor Bill Ackman Defends Support For Drug Maker Valeant
The New York Times interviews Ackman, who backs Valeant and the company's controversial drug pricing practices. In other marketplace news, U.S. prosecutors seek to extradite pharmacy officials charged with smuggling counterfeit cancer drugs.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment